We assessed the utility of the Alere i Influenza A & B point of care influenza test (Ai-24 POCIT) with laboratory testing using RT-PCR. 270 adult hospital patients had both 25
Abstract
The results of the Ai-POCIT were immediately available to ED patient care 97 coordinators, and the results were printed and placed in the patient paper record. 98
The difference in turnaround time (TAT) was calculated by comparing the Ai-POCIT 99 result time with the result release time for the laboratory NAAT and was measured in 100 days. 101
102
This study was considered to be a laboratory method audit as approved by the Clinical 103
Audit committee of the Capital and Coast and Hutt Valley District Health Boards. The 104 decision to test for influenza remained at the discretion of the treating clinician and 105 there was no change in the method for sample collection. The Alere instruments were 106 provided on loan from the manufacturer, and the manufacturer had no part in the 107 study design, data collection or analysis, or write up. Test kits were paid for utilising 108 departmental research funds. The results were used for bed allocation decisions, but 109 there was no change in policy for the use of antiviral drugs as part of the audit. 110 111 112
Results

113
The inclusion criteria requiring patients to be destined for inpatient care meant that 114 the majority of patients had significant comorbidities and reflected the normal range 115 of medical illnesses affecting patients considered for admission to hospital. The study 116 period coincided with the peak period of influenza activity as judged by syndromic 117 surveillance from the Wellington Hospital ED (data not shown). 118
119
Three hundred and twenty-one Ai-POCIT results were obtained from 302 patients, of 120 which 270 patients (89%) had laboratory influenza tests conducted on the samesample. Overall, 30% and 32% influenza tests were positive by Ai-POCIT and RT-122 PCR, respectively. During the same period, 1166 samples were received for 123 laboratory influenza testing. Of patients not having a sample sent to the laboratory, 124 the majority had an Ai-POCIT result of "not detected" (37 of 49, 76%), indicating that 125 the ED staff were less likely to send a sample to the laboratory from a patient for 126 whom they believed influenza had been ruled out. This may have skewed the results 127 assessing the sensitivity of Ai-POCIT, although samples from 163 patients with 128
negative Ai-POCIT results were received by the laboratory. The 11% failure rate significantly adds to costs and shows the importance of feedback 237 and retraining of staff. The data log from the instrument makes it easy to provide 238 individual staff feedback which would be important to maintain quality. The first 239 timed step of warm-up prior to introduction of the sample is 5-10 minutes, during 240 which other jobs may be started. Time-outs occur as a result of the staff member 241 becoming distracted. Anecdotally, this error appeared to be more frequent when ED 242 staff were conducting a test for another clinical area, rather than their own patient. The ready availability of Ai-POCIT in the ED ensured that testing happened as 287 intended. In particular the senior nurses performing the tests had an incentive to do so, 288 as without the test many patients would have required a wait for an isolation room. 289
Point of care testing should be delivered at the point of care, not merely using this 290 technology as a faster and easier method of running a laboratory. Finally by having a 291 cost of testing (of clinician time), this will have had an automatic demand 292 management effect. It is only utilised when appropriate, and not for patients who 293 would be discharged or otherwise do not need a precise microbiological diagnosis. 294
Only 18 patients received oseltamivir, 3 of whom were Ai-POCIT negative. Two of 296 these patients were also negative on laboratory influenza testing, and it is unclear why 297 this was prescribed. The final patient prescribed oseltamivir was immunosuppressed. 
